Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Xeris Pharmaceuticals revenue
Xeris Pharmaceuticals's revenue is $203.1 million.
What is Xeris Pharmaceuticals's revenue?
- Xeris Pharmaceuticals's revenue growth from 2020 to 2024 is 893.74%.
- Xeris Pharmaceuticals has 200 employees, and the revenue per employee ratio is $1,015,350.
- Xeris Pharmaceuticals's peak quarterly revenue was $60.1M in 2024(q4).
- Xeris Pharmaceuticals peak revenue was $203.1M in 2024.
- Xeris Pharmaceuticals annual revenue for 2024 was 203.1M, 23.89% growth from 2023.
- Xeris Pharmaceuticals annual revenue for 2023 was 163.9M, 48.68% growth from 2022.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Xeris Pharmaceuticals historical revenue
Xeris Pharmaceuticals's peak revenue was $203.1M in 2024. The peak quarterly revenue was $60.1M in 2024(q4).
Xeris Pharmaceuticals's revenue increased from $20.4m in 2020 to $203.1M currently. That's a 893.74% change in annual revenue.
Xeris Pharmaceuticals annual revenue
Xeris Pharmaceuticals annual revenue over time
| Fiscal year / year | Xeris Pharmaceuticals revenue |
|---|---|
| 2020 | $20.4M |
| 2021 | $49.6M |
| 2022 | $110.2M |
| 2023 | $163.9M |
| 2024 | $203.1M |
Rate Xeris Pharmaceuticals' financial transparency
Xeris Pharmaceuticals annual growth
Xeris Pharmaceuticals saw the greatest revenue growth in 2021, when revenue increased by 142.67%.
Xeris Pharmaceuticals had the lowest revenue growth in 2022, when revenue changed by 122.32%.
Xeris Pharmaceuticals annual growth rate over time
| Year | Xeris Pharmaceuticals growth |
|---|---|
| 2021 | 143%↑ |
| 2022 | 122%↑ |
| 2023 | 49%↑ |
| 2024 | 24%↑ |
Xeris Pharmaceuticals jobs nearby
Do you work at Xeris Pharmaceuticals?
Did Xeris Pharmaceuticals meet its revenue projections?
Xeris Pharmaceuticals financial information
| CEO | Paul R. Edick |
| Company Type | Public |
| Employees Number | 200 |
| Date Founded | 2005 |
| Headquarters | Chicago, Illinois |
| Number of Locations | 1 |
| Revenue | $203.1M |
| Net Income | -$94,660,000 |
| Gross Proft | $166.2M (2024) |
| EBITDA | ($21.1M) (2024) |
| Tax Rate | 0.0% |
| Total Assets | $344,522,000 |
| Ticker | XERS |
Xeris Pharmaceuticals jobs you might like
Xeris Pharmaceuticals financing
Xeris Pharmaceuticals received early financing of $1.5M on 2011-12-12.
| Series | Round size | Date |
|---|---|---|
| Series A | $1.5M | 12/2011 |
| Debt Financing | $2.3M | 07/2013 |
| Series B | $13M | 01/2015 |
| Debt Financing | $4.9M | 01/2015 |
| Series C | $41M | 01/2016 |
| Series C | $30M | 05/2017 |
| Debt Financing | $45M | 03/2018 |
| Series C | $10M | 03/2018 |
| Post Ipo Debt | $85M | 09/2019 |
| Post Ipo Equity | $27M | 03/2021 |
Xeris Pharmaceuticals investors
| Investors | Security type |
|---|---|
| Central Texas Angel Network | Series A |
| Redmile Group | Series C |
| SABBY MANAGEMENT LLC | Series C |
| Deerfield | Series C |
| McNair Group | Series C |
| Bay City Capital | Series C |
| Redmile Group | Series C |
| MERIEUX EQUITY PARTNERS | Series C |
| Palmetto Partners | Series C |
| Wild Basin Investments | Series C |
| Asahi Kasei | Series C |
| Deerfield | Series C |
| Oxford Finance LLC | Debt Financing |
| SVB Financial Group | Debt Financing |
| MERIEUX EQUITY PARTNERS | Series C |
| Wild Basin Investments | Series C |
| Oxford Finance LLC | Post Ipo Debt |
| SVB Financial Group | Post Ipo Debt |
| Deerfield | Post Ipo Equity |
Search for jobs
Xeris Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Xeris Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Xeris Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Xeris Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Xeris Pharmaceuticals. The data presented on this page does not represent the view of Xeris Pharmaceuticals and its employees or that of Zippia.
Xeris Pharmaceuticals may also be known as or be related to XERIS PHARMACEUTICALS INC, Xeris Pharmaceuticals, Xeris Pharmaceuticals Inc, Xeris Pharmaceuticals Inc. and Xeris Pharmaceuticals, Inc.